Vaxcyte, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vaxcyte, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($766.63M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($463.93M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($402.27M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($223.49M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($100.08M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($20.74M) | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | ($21.02M) | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | ($20.32M) | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | ($27.14M) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | ($14.62M) | Mar 29, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($923.68M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($569.55M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($468.04M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($232.26M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($103.67M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($19.45M) | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | ($21.31M) | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | ($21.22M) | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | ($27.60M) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | ($15.84M) | Mar 29, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $794.31M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $476.64M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $332.34M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $169.45M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $78.41M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $14.66M | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | $16.41M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $18.18M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $24.32M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $13.38M | Mar 29, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($655.58M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($452.63M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($296.79M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($170.60M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($121.39M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($46.63M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($47.15M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($30.47M) | Mar 29, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.71M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $22.43M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $16.06M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $5.84M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $6.56M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.16M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.20M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.77M | Mar 29, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.00B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.51B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.41B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.01B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $324.34M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $392.83M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $65.70M | Mar 29, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $317.21M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $205.50M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $167.45M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $52.57M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $40.32M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $46.98M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $11.76M | Mar 29, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.69B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.31B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.24B | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $953.61M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $284.02M | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | $345.84M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | ($106.37M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | ($57.73M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | ($29.13M) | Mar 29, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.15B) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($1.39B) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($924.39M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($522.13M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($298.64M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($198.56M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($109.35M) | Mar 29, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.96M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $387.88M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $397.45M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $834.66M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $68.99M | Feb 27, 2023 |
| FY2022 | Dec 31, 2020 | $386.20M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $58.98M | Feb 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 27, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 27, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 131.06M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 124.89M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 95.36M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 79.47M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 53.03M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 51.07M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 4.06M | Mar 29, 2021 |